Denali Therapeutics: Of The Form 8k Filed By Denali Therapeutics Inc. (the “company”) On December 4, 2025 Related To The Synthetic Royalty Funding Agreement Between The Company And Royalty Pharma (the “royalty Agreement”), And The Information Contained In Item 7.01 Below, Is Hereby Incorporated By Reference Into This Item 2.03 In Its Entirety, Regulation Fd Disclosure

Mostra articolo completo

Questa funzionalità è disponibile solo per gli utenti registrati

• Nome completo dell'emittente
  Denali Therapeutics Inc.
• Paese di registrazione
  USA
• Settore industriale
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***